Meeting Notices
26 April 2016
Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients
Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Timothy P. Loomis, Larry A. Mole – 26 April 2016 – Real‐world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions. The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been rapid, but variations often occur in clinical practice. The aim of this study was to assess sustained virologic response (SVR) of LDV/SOF±ribavirin (RBV) in routine medical practice.
The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor‐β1 biliary secretion in mice
Nan Wu, Fanyin Meng, Pietro Invernizzi, Francesca Bernuzzi, Julie Venter, Holly Standeford, Paolo Onori, Marco Marzioni, Domenico Alvaro, Antonio Franchitto, Eugenio Gaudio, Shannon Glaser, Gianfranco Alpini – 26 April 2016 – The secretin/secretin receptor (SR) axis is up‐regulated by proliferating cholangiocytes during cholestasis. Secretin stimulates biliary proliferation by down‐regulation of let‐7a and subsequent up‐regulation of the growth‐promoting factor, nerve growth factor (NGF).
Author Checklist
26 April 2016
Aquaporin gene therapy for disorders of cholestasis?
Lukmanee Tradtrantip, Alan S. Verkman – 26 April 2016
Reply
Robert S. Brown, Brian J. McMahon, Anna S.F. Lok, John B. Wong, Ahmed T. Ahmed, Mohamad A. Mouchli, Zhen Wang, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 26 April 2016
Statins in Cirrhosis: The Magic Pill?
Giuseppe Malizia, Gennaro D'Amico – 26 April 2016
Reply
Sudeep Banerjee, Michael D. Kuo – 26 April 2016
Reply
Guadalupe Garcia‐Tsao, Jordan Sack – 26 April 2016
Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity
Dan Liu, Lei Cui, Yuan Wang, Guifang Yang, Jing He, Ruidong Hao, Chengpeng Fan, Mengmeng Qu, Zhepeng Liu, Min Wang, Lang Chen, Hui Li, Deyin Guo – 22 April 2016 – Hepatitis B viral infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Although several viral factors have been identified that may increase the risk for HCC development, the molecular mechanisms leading to the transformation of normal hepatocytes into cancer cells remain elusive.